We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

33 hedge funds and large institutions have $1.91M invested in Acorda Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

3% more funds holding

Funds holding: 32 → 33 (+1)

38% less capital invested

Capital invested by funds: $3.08M → $1.91M (-$1.17M)

64% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 11

Holders
33
Holders Change
+1
Holders Change %
+3.13%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
11
Closed
2
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$8K

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$11.9K
2
Citigroup
Citigroup
New York
+$602
3
Morgan Stanley
Morgan Stanley
New York
+$560
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$251
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$167

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$51.8K
2
Millennium Management
Millennium Management
New York
-$50.7K
3
Renaissance Technologies
Renaissance Technologies
New York
-$19K
4
HF
HRT Financial
New York
-$18K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8.62K

ACOR Hedge Fund Activity: Q3 2022 in Review

33 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2022, worth a combined $1.91M — down 38% from $3.08M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ACOR positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 11 trimmed.

The largest buyer was Two Sigma Investments, opening a new position worth an estimated $11.9K. The largest seller was Virtu Financial, cutting an estimated $51.8K.

  • 33 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2022, up from 32 in Q2 2022.
  • Funds reported $1.91M of Acorda Therapeutics stock for Q3 2022, down 38% quarter-over-quarter.
  • 3 funds opened new Acorda Therapeutics positions in Q3 2022 and 2 closed out, a net change of +1 holder.
  • The largest Acorda Therapeutics buyer in Q3 2022 was Two Sigma Investments, an estimated $11.9K added.
  • The largest Acorda Therapeutics seller in Q3 2022 was Virtu Financial, an estimated $51.8K sold.

Based on aggregated 13F filings for Q3 2022.